Opioid Prescriptions Significantly Higher for Patients with Lifelong Disabilities

Translate to Spanish or other 102 languages!

Researchers analyzed prescriptions of opioids from private insurance claims of over 22,000 patients with cerebral palsy or spina bifida, and more than 930,000 patients without the conditions. Image for illustration purposes
Researchers analyzed prescriptions of opioids from private insurance claims of over 22,000 patients with cerebral palsy or spina bifida, and more than 930,000 patients without the conditions. Image for illustration purposes

Mega Doctor News

- Advertisement -

By Michigan Medicine – University of Michigan

Newswise — A Michigan Medicine study finds that people with two pediatric-onset neurodevelopmental disorders are prescribed opioids at significantly higher rates than those without the conditions, raising concerns over addiction, overdose and mental health issues.

Researchers analyzed prescriptions of opioids from private insurance claims of over 22,000 patients with cerebral palsy or spina bifida, and more than 930,000 patients without the conditions.

- Advertisement -

They found that oral morphine equivalents, derived from medications such as oxycodone, codeine and morphine, were prescribed to patients with cerebral palsy and spina bifida at a rate up to five times higher than patients who do not have those conditions. The higher prescription patterns spanned across people with no pain, isolated and chronic pain, according to results published in Heliyon (a Cell Press journal).

“Our findings are of great concern, given the known links between persistent opioid use and psychiatric conditions, as well as with overdose mortality,” said Mark Peterson, Ph.D., M.S., lead author of the paper and an associate professor of physical medicine and rehabilitation at University of Michigan Medical School.

Chronic pain is the most commonly reported symptom among patients with cerebral palsy, a neurological condition caused by abnormalities in the brain, and spina bifida, a neural tube defect that can damage the spinal cord and nerves. Pain in these individuals may arise from several issues, including muscle spasticity, arthritis and invasive surgical procedures.

Previous studies found that more than 40% of all Medicaid beneficiaries with a disability took opioid pain relievers, with more than 20% reporting chronic opioid use. The research team raises concerns over whether long-term opioid use is appropriate for the treatment of non-cancer-related chronic pain.

- Advertisement -

Future studies must examine the effectiveness of non-opioid pain medications and alternative pain management strategies for adults living with cerebral palsy and spina bifida, says co-author Edward Hurvitz, M.D., chair of the U-M Health Department of Physical Medicine and Rehabilitation and a professor at U-M Medical School.

“Improving clinical pain screening strategies and developing efficient referral resources for appropriate pain management may help reduce the burden of opioid addiction and overdose in these populations by matching treatments to underlying pain mechanisms,” Hurvitz said.

Additional authors include: Neil Kamdar, M.A., Jeidi J. Haapala, M.D., Chad Brummett, M.D., all of Michigan Medicine

This research was developed in part under a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR #90RTHF0001-01-00).

Paper cited: “Opioid prescription patterns among adults with cerebral palsy and spina bifida,” Heliyon. DOI: 10.1016/j.heliyon.2022.e09918

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Expands Kidney Transplant Program with Transplant Nephrologist, Dr. Victor E. Prado

As part of its ongoing commitment to bringing world-class healthcare to the Rio Grande Valley, DHR Health is pleased to announce the addition of double board-certified transplant nephrologist, Dr. Victor E. Prado. Dr. Prado will provide care to patients at DHR Health’s Transplant Institute,

New Therapy for Head and Neck Squamous Cell Carcinoma Receives Accelerated FDA Approval

The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.

DHR Health to Host 13th Annual Circle of Care Caregivers Conference

DHR Health Rehabilitation Hospital will host its 13th Annual Circle of Care Caregivers Conference on Saturday, November 7, 2026, at the Edinburg Conference Center at Renaissance, offering educational presentations and resources for individuals caring for family members and loved ones.

HHS Opens $1 Million Funding Opportunity to Strengthen Women’s Preventive Care

The U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), announced a Notice of Funding Opportunity (NOFO) for the Women’s Initiative for Screening and Health (WISH) program.
- Advertisement -